| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Takuji Inagaki, Tsuyoshi Miyaoka, Hideto Shinno, Jun Horiguchi, Shuji Matsuda, Hiroo Yoshikaw. Treatment of temporomandibular pain with the selective serotonin reuptake inhibitor paroxetine. Primary care companion to the Journal of clinical psychiatry. vol 9. issue 1. 2011-11-10. PMID:17599175. |
treatment of temporomandibular pain with the selective serotonin reuptake inhibitor paroxetine. |
2011-11-10 |
2023-08-12 |
Not clear |
| Y Takamatsu, H Yamamoto, Y Hagino, A Markou, K Iked. The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice. Current neuropharmacology. vol 9. issue 1. 2011-11-10. PMID:21886565. |
the selective serotonin reuptake inhibitor paroxetine, but not fluvoxamine, decreases methamphetamine conditioned place preference in mice. |
2011-11-10 |
2023-08-12 |
mouse |
| Clare M Mathes, Alan C Specto. The selective serotonin reuptake inhibitor paroxetine does not alter consummatory concentration-dependent licking of prototypical taste stimuli by rats. Chemical senses. vol 36. issue 6. 2011-11-08. PMID:21422376. |
the selective serotonin reuptake inhibitor paroxetine does not alter consummatory concentration-dependent licking of prototypical taste stimuli by rats. |
2011-11-08 |
2023-08-12 |
rat |
| Clare M Mathes, Alan C Specto. The selective serotonin reuptake inhibitor paroxetine does not alter consummatory concentration-dependent licking of prototypical taste stimuli by rats. Chemical senses. vol 36. issue 6. 2011-11-08. PMID:21422376. |
exogenous administration of the selective serotonin reuptake inhibitor, paroxetine, has been shown to increase taste sensitivity to stimuli described by humans as sweet and bitter. |
2011-11-08 |
2023-08-12 |
rat |
| Clare M Mathes, Alan C Specto. The selective serotonin reuptake inhibitor paroxetine does not alter consummatory concentration-dependent licking of prototypical taste stimuli by rats. Chemical senses. vol 36. issue 6. 2011-11-08. PMID:21422376. |
therefore, a systemic increase in serotonin via paroxetine administration can decrease appetitive behavior in brief-access tests but is insufficient to alter taste-guided consummatory behavior. |
2011-11-08 |
2023-08-12 |
rat |
| Koji Takeuchi, Akiko Tanaka, Kazuo Nukui, Azusa Kojo, Melinda Gyenge, Kikuko Amagas. Aggravation by paroxetine, a selective serotonin reuptake inhibitor, of antral lesions generated by nonsteroidal anti-inflammatory drugs in rats. The Journal of pharmacology and experimental therapeutics. vol 338. issue 3. 2011-10-31. PMID:21705613. |
aggravation by paroxetine, a selective serotonin reuptake inhibitor, of antral lesions generated by nonsteroidal anti-inflammatory drugs in rats. |
2011-10-31 |
2023-08-12 |
rat |
| Koji Takeuchi, Akiko Tanaka, Kazuo Nukui, Azusa Kojo, Melinda Gyenge, Kikuko Amagas. Aggravation by paroxetine, a selective serotonin reuptake inhibitor, of antral lesions generated by nonsteroidal anti-inflammatory drugs in rats. The Journal of pharmacology and experimental therapeutics. vol 338. issue 3. 2011-10-31. PMID:21705613. |
exogenous 5-ht also worsened the indomethacin-induced antral damage, whereas the aggravating effect of paroxetine was attenuated by ondansetron, a selective 5-ht(3) antagonist, but not antagonists for other 5-ht receptor subtypes. |
2011-10-31 |
2023-08-12 |
rat |
| Jean-Philippe Guilloux, Denis J P David, Lin Xia, Hai Thanh Nguyen, Quentin Rainer, Bruno P Guiard, Christelle Repérant, Thierry Deltheil, Miklos Toth, René Hen, Alain M Gardie. Characterization of 5-HT(1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology. vol 61. issue 3. 2011-10-14. PMID:21333660. |
deletion of both receptors resulted in (i) higher emotionality of animals, as observed in three unconditioned paradigms of anxiety (open field, elevated plus maze and novelty suppressed feeding tests); (ii) a ≈200% increase in the mean spontaneous firing rate of 5-ht neurons in the dorsal raphe nucleus (drn) compared to 5-ht(1a/1b)+/+ mice; (iii) elevated basal dialysate levels of 5-ht in the drn and frontal cortex; (iv) an exaggerated response to acute paroxetine administration in microdialysis experiments, and (v) increased basal core body temperature. |
2011-10-14 |
2023-08-12 |
mouse |
| Dara J Sakolsky, James M Perel, Graham J Emslie, Gregory N Clarke, Karen Dineen Wagner, Benedetto Vitiello, Martin B Keller, Boris Birmaher, Joan Rosenbaum Asarnow, Neal D Ryan, James T McCracken, Michael J Strober, Satish Iyengar, Giovanna Porta, David A Bren. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Journal of clinical psychopharmacology. vol 31. issue 1. 2011-10-13. PMID:21192150. |
adolescents (n = 334) with major depression who had not responded to a selective serotonin reuptake inhibitor (ssri) were randomized to 1 of 4 treatments: switch to another ssri (fluoxetine, citalopram, or paroxetine), switch to venlafaxine, switch to ssri plus cognitive behavior therapy, or switch to venlafaxine plus cognitive behavior therapy. |
2011-10-13 |
2023-08-12 |
human |
| Y Mizoguchi, A Monji, T A Kato, H Horikawa, Y Seki, M Kasai, S Kanba, S Yamad. Possible role of BDNF-induced microglial intracellular Ca(2+) elevation in the pathophysiology of neuropsychiatric disorders. Mini reviews in medicinal chemistry. vol 11. issue 7. 2011-10-06. PMID:21699488. |
additionally, selective serotonin reuptake inhibitors (ssris), including paroxetine or sertraline, potentiated the bdnf-induced increase in [ca(2+)]i in rodent microglial cells this article provides a review of recent findings on the role of bdnf in the pathophysiology of neuropsychiatric disorders, especially by focusing on its effect on intracellular ca(2+) signaling in microglial cells. |
2011-10-06 |
2023-08-12 |
Not clear |
| Camila Marroni Roncon, Camila Biesdorf de Almeida, Traudi Klein, João Carlos Palazzo de Mello, Elisabeth Aparecida Aud. Anxiolytic effects of a semipurified constituent of guaraná seeds on rats in the elevated T-maze test. Planta medica. vol 77. issue 3. 2011-09-26. PMID:20845263. |
the selective serotonin (5-ht) reuptake inhibitor (ssri) paroxetine (par; 3 mg/kg), was used as a positive control. |
2011-09-26 |
2023-08-12 |
rat |
| Reiji Yoshimura, Taro Kishi, Akihito Suzuki, Wakako Umene-Nakano, Atsuko Ikenouchi-Sugita, Hikaru Hori, Koichi Otani, Nakao Iwata, Jun Nakamur. The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 35. issue 4. 2011-09-13. PMID:21338649. |
we investigated the relationship between a brain-derived neurotrophic factor (bdnf) polymorphism (val66met) and the clinical response of patients with major depressive disorder to selective serotonin reuptake inhibitors (ssris; here, paroxetine and sertraline). |
2011-09-13 |
2023-08-12 |
Not clear |
| Thierry Deltheil, Kenji Tanaka, Christelle Reperant, René Hen, Denis J David, Alain M Gardie. Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. The international journal of neuropsychopharmacology. vol 12. issue 7. 2011-09-06. PMID:19236729. |
neurochemical data revealed that bdnf (100 ng) potentiated the effects of the systemic administration of a serotonin selective reuptake inhibitor (ssri; paroxetine 4 mg/kg i.p.) |
2011-09-06 |
2023-08-12 |
mouse |
| Hitoshi Zembutsu, Mitsunori Sasa, Kazuma Kiyotani, Taisei Mushiroda, Yusuke Nakamur. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert review of anticancer therapy. vol 11. issue 2. 2011-09-01. PMID:21342038. |
a review of published reports regarding the effects of selective serotonin reuptake inhibitors on the pharmacokinetics and/or efficacy of tamoxifen found that concurrent use of strong cyp2d6 inhibitors, especially paroxetine, and possibly others, should be avoided in patients receiving tamoxifen therapy, but there has not been enough evidence for the effects of weak or moderate inhibitors. |
2011-09-01 |
2023-08-12 |
Not clear |
| Elisa Cascade, Amir H Kalali, Sidney H Kenned. Real-World Data on SSRI Antidepressant Side Effects. Psychiatry (Edgmont (Pa. : Township)). vol 6. issue 2. 2011-07-14. PMID:19724743. |
specifically, data on side effects was tabulated for patients taking one of the following selective serotonin reuptake inhibitor antidepressants: citalopram, escitalopram, fluoxetine, paroxetine, and sertraline. |
2011-07-14 |
2023-08-12 |
Not clear |
| Elisa Cascade, Amir H Kalali, Uriel Halbreic. Antidepressant prescribing by specialty and treatment of premenstrual dysphoric disorder. Psychiatry (Edgmont (Pa. : Township)). vol 5. issue 12. 2011-07-14. PMID:19724771. |
obstetrician/ gynecologists more frequently use selective serotonin reuptake inhibitors (69% compared to 58% in primary care and 48% in psychiatry) and are more likely to choose an selective serotonin reuptake inhibitors agent indicated for the treatment of premenstrual dysphoric disorder (e.g., fluoxetine, paroxetine, sertraline): 66 percent versus 59 percent for both primary care physicians and psychiatrists. |
2011-07-14 |
2023-08-12 |
Not clear |
| Randy A Sansone, Lori A Sanson. Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont (Pa. : Township)). vol 5. issue 12. 2011-07-14. PMID:19724772. |
the selective serotonin reuptake inhibitors have either been less robust (paroxetine, citalopram) or lacked any efficacy at all (fluoxetine). |
2011-07-14 |
2023-08-12 |
Not clear |
| Hyun-Jung Park, Soon-Tae Lee, Ji-Young Shim, Bomie Kim, Sun-Hee Hwang, Sook-Hee Kim, Jeong-Eun Park, Jong-Ha Park, Se-Hee Jung, Jin-Young Ahn, Kon Chu, Manho Ki. The Effect of Paroxetine on the Reduction of Migraine Frequency is Independent of Its Anxiolytic Effect. Journal of clinical neurology (Seoul, Korea). vol 2. issue 4. 2011-07-14. PMID:20396527. |
paroxetine, an antidepressant, is one of the selective serotonin reuptake inhibitors (ssris) that has an anxiolytic effect, and is also known to be effective for migraine prophylaxis. |
2011-07-14 |
2023-08-12 |
Not clear |
| Shawn P Cahill, Kristin Pontoski, Carla M D'Oli. Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention. Psychiatry (Edgmont (Pa. : Township)). vol 2. issue 9. 2011-07-14. PMID:21120107. |
the selective serotonin reuptake inhibitors, sertraline, paroxetine, and fluoxetine, have been found efficacious in the treatment of chronic ptsd, with sertraline and paroxetine receiving the fda indication for this condition. |
2011-07-14 |
2023-08-12 |
Not clear |
| M Nirmala, B R Sreekanth, Peddy Vishweshwar, J Moses Babu, Y Anjaneyul. (3S,4R)-4-(4-Fluoro-phen-yl)-3-(hydroxy-meth-yl)piperidinium chloride. Acta crystallographica. Section E, Structure reports online. vol 64. issue Pt 5. 2011-07-14. PMID:21202292. |
the title compound, c(12)h(17)fno(+)·cl(-), is a degradation impurity of paroxetine hydro-chloride hemihydrate (paxil), an anti-depressant belonging to the group of drugs called selective serotonin reuptake inhibitors (ssris). |
2011-07-14 |
2023-08-12 |
Not clear |